- Cigna Medicare
- Individual & Family Plans
- International Plans
- Offered Cigna Through Work?
- Find a Doctor
- Informed on Reform
- Health and Wellness »
- Cigna Home Delivery Pharmacy
HTLV Type I and Type II
National Organization for Rare Disorders, Inc.
- Acute T-Cell Leukemia
- Acute T-Cell Lymphoma
- Tropical Spastic Paraparesis
- HTLV-I associated myelopathy
HTLV-I was first isolated in 1980 from a patient originally thought to have a cutaneous lymphoma. It became clear that it was a distinct form of lymphoma, which was designated as acute T-cell leukemia/ lymphoma (ATL). Some years later, different groups in Martinique and Japan described an association between a chronic disease of the spinal cord and HTLV-I infection, which was later named HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). Since then, several other conditions have been linked to HTLV infection.
It is estimated that between 10 and 20 million people are infected by HTLV-I in the world. Only 0.25-2% of the infected individuals will develop a progressive neurologic disease named HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). Approximately 2-5% of HTLV-I carriers will develop ATL. More rarely, HTLV-I may lead to arthropathy, uveitis (inflammation of the eye), pneumonitis and thyroid problems. Areas of the world that are endemic to the HTLV-1 virus are the Caribbean, southern Japan, equatorial Africa, Middle East, South America, and Melanesia.
WE MOVE (Worldwide Education and Awareness for Movement Disorders)
5731 Mosholu Avenue
Bronx, NY 10471
Transverse Myelitis Association
1787 Sutter Parkway
Tacoma, OH 43065-8806
Genetic and Rare Diseases (GARD) Information Center
PO Box 8126
Gaithersburg, MD 20898-8126
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email email@example.com
Last Updated: 7/30/2008
Copyright 2008 National Organization for Rare Disorders, Inc.